Immunome (IMNM) Capital Expenditures (2019 - 2026)

Immunome has reported Capital Expenditures for 8 years, with the latest figure at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 91.05% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 million (up 25.2% YoY), and the FY2025 full-year result was $1.0 million, down 64.15% from the prior year.
• Capital Expenditures for Q1 2026 stood at $1.1 million, up from -$4.7 million in the prior quarter.
• The five-year high for Capital Expenditures was $4.4 million in Q3 2025, with the low at -$4.7 million in Q4 2025.
• Historically, Capital Expenditures has averaged $376375.0 across 5 years, with a median of $255000.0 in 2022.
• Annual changes were most pronounced in 2022 — Capital Expenditures soared 2025.0% — and 2024, when it tumbled 2030.56%.
• Immunome's Capital Expenditures stood at $72000.0 in 2022, then soared by 384.72% to $349000.0 in 2023, then jumped by 549.0% to $2.3 million in 2024, then tumbled by 306.62% to -$4.7 million in 2025, then jumped by 124.17% to $1.1 million in 2026.
• The last three Capital Expenditures figures came in at $1.1 million (Q1 2026), -$4.7 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.